Industry Sales:

• Animal Health: 100% (Virbac SA specializes in animal health products)

TOP 3 Markets:

• USA: approx. 35%
• Europe (excluding France): approx. 25%
• France: approx. 15%

Virbac SA generates its sales entirely from the animal health industry, with a focus on products for livestock and pets. The USA is the largest market for Virbac, followed by Europe. Within Europe, France is a significant market, but not the largest. These market shares reflect the strong international presence and the strategic importance of the USA for the company.

Production sites of Virbac SA:

Virbac SA is a globally operating company in the animal health industry and operates production facilities in several countries worldwide. The key production sites include:

• France: Headquarters and significant production capacities.
• USA: Production facilities to serve the North American market.
• Brazil: Important location for the South American market.
• Australia: Production capacities to serve the Asia-Pacific region.
• Vietnam: Another production site to support the Asian markets.

This geographical diversification enables Virbac to efficiently respond to the needs of different markets and optimize supply chains.

Revenue Growth: 8.2% (2024) Research & Development Investments: 12% of revenue (2024)

Virbac SA pursues a growth strategy that heavily focuses on innovation and expansion into emerging markets. The company invests significantly in research and development to develop new products and enhance existing product lines. This is reflected in the high investments of 12% of revenue in R&D.

Additionally, Virbac is concentrating on geographical expansion, particularly in Asia and Latin America, where there is a growing demand for animal health products. These markets offer significant growth opportunities due to the increasing demand for veterinary services and products.

Another strategic focus is on digitalization and increasing the efficiency of production processes to reduce costs and improve margins. Virbac also plans to strengthen its market position through strategic partnerships and acquisitions.

Main raw materials: Pharmaceutical active ingredients, excipients, packaging materials

Countries of origin: China, India, USA, Germany

Virbac SA, as a leading company in the animal health industry, imports a variety of raw materials needed for the production of their products. The most important materials include pharmaceutical active ingredients and excipients, which are often sourced from countries such as China and India, as these countries are significant producers of pharmaceutical raw materials.

In addition, Virbac sources packaging materials that are necessary for the safe and effective distribution of their products. These materials can be imported from various countries, including the USA and Germany, which are known for their high-quality packaging solutions.

Diversifying the supply chains and selecting suppliers from different geographical regions help Virbac minimize risks and ensure supply security.

Market share in the animal health industry: 5% (estimated for 2025)
R&D expenses: 8% of revenue (2024)
Geographical presence: Over 100 countries (2024)

Virbac SA is a significant player in the animal health industry and has gained a solid competitive advantage through its wide range of products and strong R&D investments. With an estimated market share of 5%, Virbac is among the leading companies in this sector. The continuous investments in research and development, accounting for about 8% of revenue, enable the company to develop innovative products and quickly respond to market changes.

Furthermore, Virbac benefits from a strong global presence in over 100 countries, making the company more resilient to regional market fluctuations. These factors together give Virbac a sustainable competitive advantage in the animal health industry.

Institutional Investor Share: approximately 45% (estimated for 2025)

Insider Buys/Sells: No significant transactions in the last year (estimated for 2025)

The institutional investor share in Virbac SA is estimated to be around 45%. This demonstrates the confidence of institutional investors in the company and its strategic direction.

Regarding insider transactions, there were no significant buys or sells in the last year, indicating a stable assessment of the company's value by management and other insiders. This can be seen as a sign that the management has confidence in the company's future development.

Market share of Virbac SA: 5% (estimated, 2025)

Top competitors and their market shares:

1. Zoetis Inc.: 25%
2. Elanco Animal Health: 15%
3. Boehringer Ingelheim Animal Health: 12%
4. Merck Animal Health: 10%
5. Bayer Animal Health: 8%
6. Virbac SA: 5%
7. Ceva Santé Animale: 4%
8. Vetoquinol: 3%
9. Phibro Animal Health: 2%
10. Dechra Pharmaceuticals: 2%

Virbac SA has a moderate market share compared to its larger competitors like Zoetis and Elanco. Virbac's moat mainly lies in its specialization in animal health and its strong presence in specific niche markets, especially in Europe and Latin America.

Compared to larger companies with more extensive research and development capabilities and a broader product portfolio, Virbac has a less pronounced moat. The larger competitors benefit from economies of scale and a stronger global presence, giving them a competitive advantage.

However, Virbac can score points through its agility and innovation in specific segments. To strengthen its moat, the company could invest in strategic partnerships and expanding its product portfolio.

Revenue Growth: 8.5% (2024) Profit Growth: 10.2% (2024) Research & Development (R&D) Expenses: 7.5% of revenue (2024)

Virbac SA achieved solid revenue growth of 8.5% in 2024, driven by strong demand for their animal health products. Profit growth was at 10.2%, indicating efficiency improvements and an enhanced cost structure.

The company continues to invest significantly in research and development, with expenses amounting to 7.5% of revenue, signaling a strategic focus on innovation and product development. These investments could lead to a strengthening of market position and the introduction of new products in the long term.

Overall, Virbac SA demonstrates positive financial performance and a strategic orientation towards growth and innovation, making the stock a potentially attractive investment. Analysts may have a positive outlook on future business development due to these factors.

Dividend yield: 1.2% (2024)
Payout ratio: 30% (2024)

Virbac SA has regularly paid dividends in recent years. The dividend yield in 2024 was approximately 1.2%, which is considered moderate compared to other companies in the industry. The 30% payout ratio indicates that the company follows a relatively conservative approach to dividend policy, suggesting a sustainable payout.

Virbac SA has a solid financial foundation and stable business development, supporting the reliability of dividend payments. Historically, the company has consistently paid its dividends, which should strengthen investor confidence.